The Medical Letter on Drugs and Therapeutics
Ivacaftor (Kalydeco) for Cystic Fibrosis
April 16, 2012 (Issue: 1388)The FDA has approved ivacaftor (eye va kaf’ tor; Kalydeco – Vertex) for oral treatment of cystic fibrosis (CF) in patients ≥6 years old with the G551D mutation, which is found in about 5% of patients with CF. It is the first drug approved...more
4. Wholesale acquisition cost (WAC) according to the manufacturer.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.